ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 50 Million

Core Viewpoint - ONWARD Medical N.V. is launching a capital increase through a private placement aimed at raising approximately EUR 50 million to support its operations and development initiatives in neurotechnology for spinal cord injuries and movement disabilities [1][2]. Summary by Sections Private Placement Overview - The private placement will involve the issuance of new ordinary shares with a nominal value of EUR 0.12 each, offered to qualified institutional investors [1][3]. - The final number of shares and the issue price will be determined through a bookbuilding process, which is expected to last one business day [4][5]. Use of Proceeds - The net proceeds from the private placement will be allocated as follows: - 40% for product development, clinical studies, and regulatory activities for the ARC-IM System - 30% to expand sales and operations for the ARC-EX System - 20% to support quality and administrative activities - 5% for working capital and general corporate purposes - 5% to cover financing costs, including existing debt obligations [2][6]. Trading and Regulatory Aspects - Trading of ONWARD Medical's shares will be temporarily suspended on Euronext Brussels, Amsterdam, and Paris during the bookbuilding period to facilitate broader investor participation [5][7]. - The new shares are expected to be listed and admitted to trading on October 28, 2025, with payment and delivery occurring on the same day [9]. Company Background - ONWARD Medical is a leading neurotechnology company focused on therapies to restore movement and independence in individuals with spinal cord injuries and other movement disabilities [11]. - The company has developed the ARC Therapy and has received multiple Breakthrough Device Designations from the FDA for its products [11].